Browse our 650+ Publications
Latest Publications
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
Tasi Y, et al.
May 2022
Authors and Affiliates
Yo-Ting Tsai 1, Julius Strauss 1, Nicole J Toney 1, Caroline Jochems 1, David J Venzon 2, James L Gulley 3, Jeffrey Schlom #,4, Renee N Donahue #,1;
1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
2 Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
3 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
4 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA schlomj@mail.nih.gov.
# Contributed equally.
T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity
Elyanow R, et al.
JCI Insight
May 2022
Authors and Affiliates
Rebecca Elyanow 1, Thomas M Snyder 1, Sudeb C Dalai 1 2, Rachel M Gittelman 1, Jim Boonyaratanakornkit 3,4, Anna Wald 3,4,5,6, Stacy Selke 6, Mark H Wener 3,6, Chihiro Morishima 6, Alexander L Greninger 6, Michael Gale Jr 7,8,9, Tien-Ying Hsiang 7, Lichen Jing 3, Michael R Holbrook 10, Ian M Kaplan 1, H Jabran Zahid 11, Damon H May 1, Jonathan M Carlson 11, Lance Baldo 1, Thomas Manley 1, Harlan S Robins 1, David M Koelle 3,4,6,9,12;
1 Adaptive Biotechnologies, Seattle, Washington, USA.
2 Stanford University School of Medicine, Stanford, California, USA.
3 Department of Medicine, University of Washington, Seattle, Washington, USA.
4 Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
5 Department of Epidemiology.
6 Department of Laboratory Medicine and Pathology.
7 Department of Immunology.
8 Department of Microbiology, and.
9 Department of Global Health, University of Washington, Seattle, Washington, USA.
10 National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility, Frederick, Maryland, USA.
11 Microsoft Research, Redmond, Washington, USA.
12 Benaroya Research Institute, Seattle, Washington, USA.
PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors
Duhen R, et al.
Journal of Clinical Investigation
May 2022
Authors and Affiliates
Rebekka Duhen 1, Olivier Fesneau 1, Kimberly A Samson 1, Alexandra K Frye 1, Michael Beymer 1, Venkatesh Rajamanickam 1, David Ross 1, Eric Tran 1, Brady Bernard 1, Andrew D Weinberg 1, Thomas Duhen 1;
1 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, United States of America.
Longitudinal analysis of T-cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection
Gittelman RM, et al.
JCI Insight
May 2022
Authors and Affiliates
Rachel M Gittelman 1, Enrico Lavezzo 2, Thomas M Snyder 1, H Jabran Zahid 3, Cara L Carty 1, Rebecca Elyanow 1, Sudeb C Dalai 1, Ilan Kirsch 1, Lance Baldo 1, Laura Manuto 2, Elisa Franchin 2, Claudia Del Vecchio 2, Monia Pacenti 4, Caterina Boldrin 4, Margherita Cattai 4, Francesca Saluzzo 5, Andrea Padoan 6, Mario Plebani 6, Fabio Simeoni 7, Jessica Bordini 8, Nicola I Lorè 5, Dejan Lazarević 7, Daniela Maria Cirillo 5, Paolo Ghia 9, Stefano Toppo 2, Jonathan M Carlson 3, Harlan S Robins 1, Andrea Crisanti 10, Giovanni Tonon 7;
1 Computational Biology, Adaptive Biotechnologies, Seattle, United States of America.
2 Department of Molecular Medicine, University of Padova, Padua, Italy.
3 eScieince Group, Microsoft Research, Redmond, United States of America.
4 Azienda Ospedale Padova, Microbiology and Virology Unit, Azienda Ospedale Padova, Microbiology and Virology Unit, Padua, Italy.
5 Division of Immunology, Transplantation and Infectious Disease, IRCCS San Raffaele Scientific Institute, Milan, Italy.
6 Department of Medicine, University of Padova, Padua, Italy.
7 Center for Omics Sciences, COSR, IRCCS San Raffaele Scientific Institute, Milan, Italy.
8 Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
9 Division of Molecular Oncology, Università Vita-Salute San Raffaele, Milan, Italy.
10 Department of Life Sciences, Imperial College London, London, United Kingdom.
Durable Expansion of TCR-δ Meta-Clonotypes After BCG Revaccination in Humans
James CA, et al.
Frontiers in Immunology
May 2022
Authors and Affiliates
Charlotte A James 1, Krystle K Q Yu 1, Koshlan Mayer-Blackwell 2, Andrew Fiore-Gartland 2, Malisa T Smith 1, Erik D Layton 1, John L Johnson 3, Willem A Hanekom 4, Thomas J Scriba 4, Chetan Seshadri 1,5;
1 Department of Medicine, University of Washington, Seattle, WA, United States.
2 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
3 Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH, United States.
4 South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
5 Tuberculosis Research and Training Center, University of Washington, Seattle, WA, United States.
Distinct phenotypic states and spatial distribution of CD8 + T cell clonotypes in human brain metastases
Sudmeier LJ, et al.
Cell Reports Medicine
May 2022
Authors and Affiliates
Lisa J Sudmeier 1, Kimberly B Hoang 2, Edjah K Nduom 2, Andreas Wieland 3, Stewart G Neill 4, Matthew J Schniederjan 4, Suresh S Ramalingam 5, Jeffrey J Olson 2, Rafi Ahmed 6, William H Hudson 7;
1 Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
2 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA, USA.
3 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.
4 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
5 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
6 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: rahmed@emory.edu.
7 Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: william.hudson@emory.edu.
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
Whangbo J, et al.
Blood Advances
May 2022
Authors and Affiliates
Jennifer Whangbo 1, Sarah Nikiforow 2, Haesook T Kim 2, Jonathan Wahl 2, Carol G Reynolds 3, Sharmila Chamling Rai 4, Soomin Kim 5, Andrew Thomas Burden 2, Ana Alho 6, João F Lacerda 7, Edwin P Alyea 8, Corey S Cutler 9, Vincent T Ho 2, Joseph H Antin 2, Robert J Soiffer 2, Jerome Ritz 2, John Koreth 2;
1 Boston Children's Hospital, United States.
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
3 Dana-Farber Cancer Institute, BOSTON, Massachusetts, United States.
4 Dana Farber Cancer Institute, Quincy, Massachusetts, United States.
5 Dana-Farber Cancer Institute, Seoul, Korea, Republic of.
6 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Algés, Portugal.
7 Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, Lisbon, Portugal.
8 Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, United States.
9 Dana Farber Cancer Institute, Boston, Massachusetts, United States.
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy
Shanavas M, et al.
Clinical Translational Immunology
May 2022
Authors and Affiliates
Mohamed Shanavas 1,2, Soi-Cheng Law 1, Mark Hertzberg 3, Rodney J Hicks 4, John F Seymour 5, Zhixiu Li 6, Lilia Merida de Long 1, Karthik Nath 1, Muhammed B Sabdia 1, Jay Gunawardana 1, Maher K Gandhi 1,7, Colm Keane 1,7;
1 Mater Research University of Queensland Brisbane QLD Australia.
2 Department of Haematology Mater Hospital Brisbane QLD Australia.
3 Department of Haematology Prince of Wales Hospital and University of NSW Randwick NSW Australia.
4 Department of Cancer Imaging Peter MacCallum Cancer Centre East Melbourne Melbourne VIC Australia.
5 Department of Haematology Peter MacCallum Cancer Centre Royal Melbourne Hospital & University of Melbourne Parkville VIC Australia.
6 Centre for Genomics and Personalised Health School of Biomedical Sciences, Faculty of Health Translational Research Institute Queensland University of Technology (QUT) Woolloongabba QLD Australia.
7 Department of Haematology Princess Alexandra Hospital Brisbane QLD Australia.
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
Chen R, et al.
May 2022
Authors and Affiliates
Runzhe Chen 1,2,3, Jun Li 2,4, Junya Fujimoto 5, Lingzhi Hong 1, Xin Hu 2, Kelly Quek 1,2, Ming Tang 2, Akash Mitra 2, Carmen Behrens 1, Chi-Wan Chow 5, Peixin Jiang 1, Latasha D Little 2, Curtis Gumbs 2, Xingzhi Song 2, Jianhua Zhang 2, Dongfeng Tan 6, John V Heymach 1, Ignacio Wistuba 5, P Andrew Futreal 2, Don L Gibbons 7, Lauren A Byers 8, Jianjun Zhang 9,10, Alexandre Reuben 11;
1 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
2 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
3 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, Guangdong, China.
4 Regor Therapeutics, 2445 Main Street, Second Floor, MA, 02142, Cambridge, USA.
5 Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
6 Department of Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
7 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dlgibbon@mdanderson.org.
8 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. lbyers@mdanderson.org.
9 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
10 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
11 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. areuben@mdanderson.org.